
    
      To identify the efficacy of Certolizumab Pegol (CZP) on synovitis in dynamic MRI parameters;
      to make the correlation between European League Against Rheumatism (EULAR), American College
      of Rheumatology (ACR)p, Disease Activity Score-28 (DAS 28) responses, and Digital XRay (DXR)
      assessment with reduction of synovitis.
    
  